Questionnaire and Laboratory Data on Vitiligo Vulgaris
Demographic and Laboratory Data Collection for Patients With Vitiligo Vulgaris
1 other identifier
observational
57
1 country
2
Brief Summary
Vitiligo vulgaris is an autoimmune disorder that causes loss of pigmentation over the skin, hair and mucous membranes (e.g. lips, nose, genitals). While genes have been identified that are thought to be required for development of vitiligo, only 5-10% of relatives develop disease. The triggers for disease onset have not yet been identified. The intent of this study is to research trends in laboratory data, social and medical history that may be contributory to vitiligo onset, location of disease, course of illness and response to therapy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Aug 2010
Longer than P75 for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2010
CompletedFirst Submitted
Initial submission to the registry
September 20, 2010
CompletedFirst Posted
Study publicly available on registry
September 21, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2014
CompletedMay 25, 2015
May 1, 2015
2 months
September 20, 2010
May 22, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Quality of life disturbances in people with vitiligo
dermatology life quality indices were you used and correlated with location of disease
point prevalence
Secondary Outcomes (1)
self-reporting of vitiligo disease symptoms and history
single survey
Eligibility Criteria
All patients willing to sign consent, complete questionnaire and/ or laboratory studies.
You may qualify if:
- Diagnosis of Vitiligo Vulgaris
- Ability to sign consent
You may not qualify if:
- Pregnant
- Inability to sign consent
- Inability to complete questionnaire
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- St. Luke's-Roosevelt Hospital Centerlead
- Beth Israel Medical Centercollaborator
Study Sites (2)
Department of Dermatology, Beth Israel Medical Center
New York, New York, 10003, United States
Department of Dermatology, St. Luke's-Roosevelt Hospital Center
New York, New York, 10025, United States
Related Publications (3)
Silverberg NB. Update on childhood vitiligo. Curr Opin Pediatr. 2010 Aug;22(4):445-52. doi: 10.1097/MOP.0b013e32833b6ac3.
PMID: 20616733BACKGROUNDSilverberg JI, Silverberg AI, Malka E, Silverberg NB. A pilot study assessing the role of 25 hydroxy vitamin D levels in patients with vitiligo vulgaris. J Am Acad Dermatol. 2010 Jun;62(6):937-41. doi: 10.1016/j.jaad.2009.11.024.
PMID: 20466170BACKGROUNDPagovich OE, Silverberg JI, Freilich E, Silverberg NB. Thyroid abnormalities in pediatric patients with vitiligo in New York City. Cutis. 2008 Jun;81(6):463-6.
PMID: 18666385BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Nanette Silverberg, MD
StLukesNY
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 20, 2010
First Posted
September 21, 2010
Study Start
August 1, 2010
Primary Completion
October 1, 2010
Study Completion
September 1, 2014
Last Updated
May 25, 2015
Record last verified: 2015-05